Antiparasitic Drugs Market Size & Share 2026-2035

Antiparasitic Drugs Market Size

The antiparasitic drugs market was valued at USD 20.7 billion in 2025. The market is expected to grow from USD 21.7 billion in 2026 to USD 36.2 billion in 2035, at a CAGR of 5.8% during the forecast period, according to the latest report published by Global Market Insights Inc.

High market growth can be attributed to factors such as rising prevalence of parasitic infections, increasing global travel and migration, and increasing public awareness campaigns and educational programs.

For instance, according to the World Health Organization, over 600 million people were estimated to be infected by Strongyloides stercoralis (helminthic), with highest prevalence reported in sub-Saharan Africa, China, South America, and Asia. Such high prevalence of parasitic infections globally contributes to a growing disease burden. This rise in the number of infected individuals creates a greater demand for effective treatment options, thereby driving the antiparasitic drugs market.

Antiparasitic drugs are a class of medications specifically designed to treat infections caused by parasitic organisms. Parasites are living organisms that depend on other organisms, known as hosts, for their survival and reproduction. Parasites can include various types of organisms, such as protozoa, helminths and arthropods. Antiparasitic drugs act by different mechanisms, such as killing the parasite, inhibiting its growth and reproduction, or interfering with its ability to infect the host.

Key players in the antiparasitic drugs market include Dr. Reddy’s Laboratories, Glenmark Pharmaceuticals, Amneal Pharmaceuticals, Novartis, Merck & Co., GlaxoSmithKline, Bayer, Ipca Laboratories and Cipla. These companies continue to drive innovation through strong research and development pipelines, expansion of antiparasitic product portfolios, advancements in formulation technologies, and strategic acquisitions aimed at strengthening global manufacturing capacities and distribution reach. Their initiatives play a critical role in addressing the long-term health challenges associated with parasitic in populations worldwide.

Between 2022 and 2024, the antiparasitic drugs market witnessed steady growth, supported by the increasing prevalence of parasitic infections, rising awareness of preventive antiparasitic drugs, and growing adoption of combination therapies. During this period, the global market expanded from approximately USD 17.9 billion in 2022 to USD 19.7 billion in 2024 at a historical growth rate of 4.8%. The global market expanded consistently, driven by strong demand for novel parasiticides and improved diagnostics across key regions. Growth was further reinforced by increased investment in pharmaceuticals, regulatory approvals of new drug formulations, and broader access to advanced treatment options across developed as well as emerging markets.

Antiparasitic Drugs Market Trends

• Surging government initiatives and increased funding has emerged as a pivotal driver propelling the antiparasitic drugs industry.
• Recognizing the profound impact of parasitic infections on public health, governments worldwide have intensified efforts to address these issues by allocating substantial resources towards research, development, and distribution of antiparasitic drugs.
• For instance, U.S. President’s Malaria Initiative (PMI), led by USAID, is a significant government initiative that contributes to market growth in the antiparasitic drugs sector.
• Further, financial support facilitates advancements in drug discovery services, encourages innovative treatment approaches, and enhances the accessibility of antiparasitic medications.
• Thus, with continuous efforts from governments and healthcare organizations, the antiparasitic drugs market is anticipated to witness continuous growth over the forecast years.
• However, development of drug resistance to certain drugs leads to a decrease in the effectiveness of antiparasitic drugs.
• Parasites that have developed resistance are less susceptible to the drugs, rendering standard treatment regimens less effective. This can lead to persistent symptoms, increased morbidity, and a higher risk of complications. Thus, impeding the growth of the market.

Antiparasitic Drugs Market Analysis

Based on drug type, the antiparasitic drugs market is segmented into anthelmintics, antiprotozoal, ectoparasiticides and other drug types. The anthelminthics segment is expected to reach the largest market revenue of USD 18 billion by 2035.

• Helminthic infections, caused by parasitic worms, remain highly prevalent across developing regions, particularly in tropical and subtropical areas where sanitation and hygiene conditions are limited, making them a major global public health concern.
• For instance, according to the Pan American Health Organization, nearly 1.5 billion people are affected by soil-transmitted helminths worldwide, representing one of the most widespread infections globally. Additionally, the Centers for Disease Control and Prevention estimates that approximately 807 to 1,121 million individuals are infected with Ascaris alone, highlighting the significant disease burden.
• Anthelmintics drugs are designed to target a wide range of helminths, including nematodes (roundworms), cestodes (tapeworms), and trematodes (flukes). Their broad-spectrum efficacy enables treatment across multiple parasitic infections, thereby supporting strong segmental growth and increasing clinical adoption.
• Further, the anthelmintics segment continues to witness steady demand due to large-scale deworming programs, inclusion in essential medicine lists, and sustained procurement by governments and global health organizations, ensuring consistent market expansion.
• Likewise, the antiprotozoal drugs segment is expected to be the fastest-growing category, stimulated by the increasing incidence of protozoal diseases such as malaria, giardiasis, and leishmaniasis, coupled with the development of novel combination therapies aimed at improving treatment efficacy and overcoming resistance.

Based on route of administration, the antiparasitic drugs is classified into injectable, oral, and topical. The oral segment held the largest market revenue of USD 11.2 billion in 2025.

• The oral segment holds a significant share in the antiparasitic drugs market, primarily due to its ease of administration, high patient compliance, and widespread availability. Oral formulations such as tablets, capsules, and suspensions are commonly used for both helminthic and protozoal infections, making them a preferred choice across diverse patient populations, including pediatric and geriatric groups.
• Additionally, oral antiparasitic drugs such as albendazole, ivermectin, and metronidazole are widely incorporated into large-scale public health programs, including mass drug administration campaigns targeting neglected tropical diseases. Their cost-effectiveness and convenience further support their adoption across both developed and emerging markets.
• Additionally, several oral antiparasitic therapies continue to be evaluated in ongoing clinical trials aimed at improving efficacy, reducing dosing frequency, and overcoming emerging drug resistance. These advancements are expected to strengthen the segment’s long-term growth by enhancing therapeutic outcomes and expanding treatment indications.
• In contrast, the topical segment is projected to be the fastest-growing segment in the antiparasitic drugs market, stimulated by increasing demand for targeted drug delivery, reduced systemic side effects, and improved patient convenience. Topical formulations such as creams, lotions, and transdermal solutions are gaining traction.

Based on distribution channel, the antiparasitic drugs market is divided into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest market share of 42.8% in 2025.

• Hospital pharmacies maintain a diverse range of antiparasitic medications, ensuring comprehensive treatment options for various parasitic infections. Additionally, hospitals serve as the primary point of care for patients with severe or complicated parasitic conditions, further leading to increased patient footfall in these pharmacies.
• Moreover, these pharmacies along with their skilled staffs provide a controlled environment and center for the administration of drugs, ensuring accurate dosing, monitoring, and management of potential side effects. All these factors together boost segmental growth.
• On the other hand, the online pharmacies segment is expected to be the fastest-growing distribution channel in the antiparasitic drugs market, driven by increasing digital adoption, convenience in medicine procurement, and expanding access to prescription and over-the-counter antiparasitic treatments.

North America Antiparasitic Drugs Market

The North America antiparasitic drugs industry dominated the market with a market share of 36.3% in 2025.

• High market growth can be attributed to increasing cases of parasitic infections in the region. For instance, according to the World Health Organization, in 2024, more than estimated 282 million cases and 610,000 deaths were reported in North America. Furthermore, as per the report published by the Sepsis Organization, toxoplasmosis and giardia infections are the two most common parasitic infections in North America.
• Further, North America, particularly the U.S., has one of the highest levels of healthcare spending globally. This substantial investment in healthcare infrastructure and services contributes to the prominence of the region in various pharmaceutical markets, including antiparasitic drugs.
• Such aforementioned factors are expected to propel the antiparasitic drugs in the North American market.

The U.S. antiparasitic drugs market was valued at USD 6.1 billion and USD 6.3 billion in 2022 and 2023, respectively. The market size reached USD 6.8 billion in 2025, growing from USD 6.6 billion in 2024.

• The U.S. maintains leadership due to advanced diagnostic capabilities, high treatment accessibility, and strong surveillance systems for parasitic diseases.
• Additionally, increasing adoption of telehealth and e-prescriptions is improving access to antiparasitic medications, particularly for underserved populations and rural communities.
• The market is further supported by ongoing clinical trials focused on improving drug efficacy and addressing resistance, along with strong regulatory frameworks ensuring timely approvals of new therapies.

Europe Antiparasitic Drugs Market

Europe antiparasitic drugs industry accounted for USD 5.9 billion in 2025 and is anticipated to show lucrative growth over the forecast period.

• Regional growth is supported by coordinated parasite control programs and strict hygiene standards. According to the European Centre for Disease Prevention and Control (ECDC), foodborne parasitic infections such as echinococcosis and trichinellosis continue to be monitored actively across member states.
• Also, increased cross-border travel within the EU contributes to transmission risks, thereby supporting demand for preventive and therapeutic antiparasitic drugs.

Germany dominates the Europe antiparasitic drugs market, with strong growth potential.

• Germany leads the regional market due to strong healthcare infrastructure and advanced laboratory diagnostics enabling early detection of parasitic infections.
• The country benefits from high awareness regarding zoonotic diseases and food safety monitoring systems, strengthening drug utilization.
• Further, the high cases of parasitic infection in Germany annually, reinforcing consistent demand for treatment solutions.

Asia Pacific Antiparasitic Drugs Market

The Asia Pacific antiparasitic drugs industry is anticipated to grow at the highest CAGR of 7% during the analysis timeframe.

• Growth is driven by tropical climatic conditions that favor parasite transmission, along with dense population clusters in countries such as India and China.
• Governments across the region are implementing large-scale deworming and malaria elimination programs, significantly boosting drug demand.
• Also, expanding healthcare infrastructure and rising investment in pharmaceutical manufacturing are further accelerating market development.

China antiparasitic drugs market is estimated to grow with a significant CAGR, in the Asia Pacific market.

• China shows strong growth due to large population size and ongoing public health initiatives targeting parasitic diseases such as schistosomiasis.
• Moreover, rising research and development investments and participation in clinical trials for novel antiparasitic therapies are strengthening the country’s position in the global market.
• Also, increasing urbanization and healthcare awareness are also contributing to higher diagnosis and treatment rates.

Latin American Antiparasitic Drugs Market

Brazil leads the Latin American antiparasitic drugs industry, exhibiting remarkable growth during the analysis period.

• Brazil holds a dominant position due to high prevalence of parasitic diseases in tropical regions and strong government-led health campaigns.
• Expansion of public healthcare programs ensures widespread distribution of essential antiparasitic medications.
• Further, increasing partnerships with global pharmaceutical companies are improving local manufacturing capacity and drug accessibility.

Middle East and Africa Antiparasitic Drugs Market

Saudi Arabia antiparasitic drugs industry is expected to experience substantial growth in the Middle East and Africa market in 2025.

• Saudi Arabia is experiencing notable growth, supported by increasing healthcare investments and national disease control initiatives under Vision 2030.
• The country is strengthening its infectious disease management systems, including improved screening and diagnosis of parasitic infections.

Antiparasitic Drugs Market Share

The global antiparasitic drugs industry is characterized by a moderately consolidated yet competitive landscape, with a select group of key players accounting for a significant share of global revenues. GlaxoSmithKline, Novartis, Sanofi, Dr. Reddy’s Laboratories and Cipla collectively contribute approximately 45% of the global market, supported by their strong product portfolios, established presence in both branded and generic drug segments, and extensive global distribution networks. These companies maintain leadership across key therapeutic areas, including anthelmintics and antiprotozoals, leveraging capabilities in large-scale production, public health program participation, and broad geographic reach.

Competitive dynamics are increasingly shaped by strategic initiatives such as portfolio expansions, geographic penetration in high-burden regions, and investments in cost-effective manufacturing. For instance, leading players are strengthening their market positions through partnerships with global health organizations and participation in mass drug administration programs, particularly for neglected tropical diseases. Additionally, continuous innovation through clinical trials focused on improved formulations, combination therapies, and resistance management is playing a critical role in sustaining market competitiveness. The evolving landscape is further driven by rising disease prevalence, increasing awareness, and the need for accessible and affordable antiparasitic treatment solutions globally.

Antiparasitic Drugs Market Companies

Prominent players operating in the antiparasitic drugs industry are as mentioned below:

• AdvaCare Pharma
• Ajanta Pharma
• Alkem Laboratories
• Cadila Pharmaceuticals
• Cipla
• Dr. Reddy’s Laboratories
• GlaxoSmithKline
• Intas Pharmaceuticals
• Ipca Laboratories
• Mankind Pharma
• Novartis
• Sanofi
• Teva Pharmaceuticals
• Weefsel Pharma
• Zydus Lifesciences

• Novartis

Novartis maintains a leading position in the antiparasitic drug market through its strong portfolio of antimalarial therapies, particularly artemisinin‑based combination treatments such as Coartem. The company benefits from extensive collaborations with global health organizations and governments, enabling large‑scale access to life‑saving treatments in malaria-endemic regions. Novartis continues to strengthen its pipeline through ongoing R&D initiatives targeting drug resistance and next-generation therapies, further reinforcing its long-term presence and leadership in protozoal disease management.

• GlaxoSmithKline (GSK)

GlaxoSmithKline maintains a strong competitive position in the antiparasitic drugs market, driven by its well-established albendazole portfolio and significant role in global deworming initiatives. The company leverages its extensive global distribution network and partnerships with public health organizations to ensure accessibility of treatments in high-burden regions. GSK continues to focus on innovation through ongoing clinical trials, improved formulations, and targeted programs for neglected tropical diseases, reinforcing its long-term growth and market presence.

Antiparasitic Drugs Industry News

• In September 2024, Alembic Pharmaceuticals received USFDA approval for Albendazole Tablets (200 mg), expanding the availability of generic antiparasitic treatments for neurocysticercosis and hydatid disease.
• In July 2021, Dr.Reddy's Laboratories, received the U.S. FDA approval to launch hydroxychloroquine sulfate tablets for the treatment of malaria. This helped the company to increase its product portfolio and generate higher sales.

The global antiparasitic drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2022 to 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Type

• Anthelmintics
• Antiprotozoal
• Ectoparasiticides
• Other drug types

Market, By Route of Administration

• Injectable
• Oral
• Topical

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE